Ryan Gottfredson
Public Health & General Preventive Medicine · Jbsa Lackland, TXNPI 1447562616
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $203 and has fallen 79.9% since, to $41 in 2025.
Across 28 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cranial Technologies, Inc$93
- Sobi, Inc$86
- Tris Pharma Inc$70
- Pfizer$50
- AstraZeneca$37
- Corium, LLC$24
- plus $129 from 8 others
Across 238 payments — averaging $4773.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$617K
- Sanofi Pasteur Inc.$483K
- Pfizer$30K
- Merck$6K
What the payments were for
- Food & beverage$490100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cranial Technologies, Inc | 5 | $93 |
| Sobi, Inc | 5 | $86 |
| Tris Pharma Inc | 4 | $70 |
| Pfizer | 3 | $50 |
| AstraZeneca | 2 | $37 |
| Corium, LLC | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Neurelis, Inc. | 1 | $15 |
| Verrica Pharmaceuticals Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$490 in reported general payments places this provider in the 80th percentile of 41 public health & general preventive medicine providers in Texas.
See all public health & general preventive medicine providers in Texas →
Other public health & general preventive medicine in Jbsa Lackland
- Erin WinklerJbsa Lackland$250
- Christopher LucciRockport$901K
- James SheehanFort Sam Houston$287K
- Barry DavisHouston$57K
- Richard LeconeyAlvin$24K
- Tyler CooperDallas$2K
- Prathima NagireddyFort Worth$2K
- John CarloDallas$1K
- Olivia IvyAustin$685
- Steven ClarkDallas$476
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.